P2Y12 antagonists as antiplatelet agents - Recent developments

Current Opinion in Drug Discovery and Development

Volumn 13, Issue 4, 2010, Pages 497-506

  Bhavaraju, Kamala ^a   Mayanglambam, Azad ^a   Rao, A Koneti ^a   Kunapuli, Satya P ^a  

^a TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Adp; antiplatelet therapy; cangrelor; elinogrel; prasugrel; purinoreceptor P2y12 antagonist; thienopyridine; ticagrelor

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; CANGRELOR; CLOPIDOGREL; CYTOCHROME P450 2B6; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 3A; ELINOGREL; PRASUGREL; PURINERGIC P2Y12 RECEPTOR; TICAGRELOR; UNCLASSIFIED DRUG; P2RY12 PROTEIN, HUMAN; PURINERGIC P2 RECEPTOR ANTAGONIST;

BLOOD CLOT LYSIS; DIZZINESS; DOSAGE SCHEDULE COMPARISON; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DYSPNEA; HEART INFARCTION; HEMATURIA; HUMAN; NONHUMAN; RECEPTOR BINDING; REVIEW; SINGLE DRUG DOSE; THROMBOCYTE AGGREGATION INHIBITION; TREATMENT DURATION; ANIMAL; CHEMICAL STRUCTURE; CHEMISTRY; CLINICAL TRIAL (TOPIC); CORONARY DISEASE; DRUG DEVELOPMENT; PROCEDURES; TRENDS;

ANIMALS; CLINICAL TRIALS AS TOPIC; CORONARY DISEASE; DRUG DISCOVERY; HUMANS; MODELS, MOLECULAR; PLATELET AGGREGATION INHIBITORS; RECEPTORS, PURINERGIC P2; PURINERGIC P2 RECEPTOR ANTAGONISTS; RECEPTORS, PURINERGIC P2Y12;

EID: 77954652853     PISSN: 13676733     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (64)

1. Shattil SJ, Kashiwagi H, Pampori N: Integrin signaling: The platelet paradigm. Blood (1998)91(8):2645-2657.
2. Kahner BN, Shankar H, Murugappan S, Prasad GL, Kunapuli SP: Nucleotide receptor signaling in platelets. J Thromb Haemost (2006)4(11):2317-2326.
3. 1 receptor-null mice. J Clin Invest (1999)104(12):1731-1737.
4. Foster CJ, Prosser DM, Agans JM, Zhai Y, Smith MD, Lachowicz JE, Zhang FL, Gustafson E, Monsma FJ Jr, Wiekowski MT, Abbondanzo SJ et al: Molecular identification and characterization of the platelet ADP receptor targeted by thienopyridine antithrombotic drugs. J Clin Invest (2001)107(12):1591-1598.
5. 3 activation: Association with Rap1B activation. J Thromb Haemost (2006)4(6):1379-1387.
6. 12 regulates platelet adhesion/activation, thrombus growth, and thrombus stability in injured arteries. J Clin Invest (2003)112(3):398-406.
7. 12 receptor blockade and its clinical implications.
8. Kunapuli SP, Ding Z, Dorsam RT, Kim S, Murugappan S, Quinton TM: ADP receptors - Targets for developing antithrombotic agents. Curr Pharm Des (2003)9(28):2303-2316.
9. van Gestel MA, Heemskerk JW, Slaaf DW, Heijnen VV, Reneman RS, oude Egbrink MG: In vivo blockade of platelet ADP receptor P2Y12 reduces embolus and thrombus formation but not thrombus stability. Arterioscler Thromb Vasc Biol (2003)23(3):518-523.
10. 12 inhibitors. Circulation (2010)121(1):171-179.
11. Grove EL, Storey RF: The right oral antithrombotics in acute coronary syndromes. Lancet (2009)374(9706):1947-1948.
12. Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, Horrow J, Husted S, James S, Katus H, Mahaffey KW et al: Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med (2009)361(11):1045- 1057. •• Summarizes the findings of the PLATO clinical trial. Results from this trial demonstrated no significant differences in the rate of major bleeding between the ticagrelor and clopidogrel groups. Dyspnea was more common in the ticagrelor group than in the clopidogrel group.
13. Smyth SS, Woulfe DS, Weitz JI, Gachet C, Conley PB, Goodman SG, Roe MT, Kuliopulos A, Moliterno DJ, French PA, Steinhubl SR et al: G-protein-coupled receptors as signaling targets for antiplatelet therapy. Arterioscler Thromb Vasc Biol (2008)29(4):449-457.
14. Cattaneo M: Laboratory detection of 'aspirin resistance': What test should we use (if any)? Eur Heart J (2007)28(14):1673-1675. • Details the criterion for aspirin resistance in patients and provides some insights into proper diagnostic tests that can detect this resistance.
15. Tantry US, Mahla E, Gurbel PA: Aspirin resistance. Prog Cardiovasc Dis (2009)52(2):141-152.
16. Gurbel PA, Tantry US: Clopidogrel resistance? Thromb Res (2007)120(3):311-321.
17. Björklund L, Wallander MA, Johansson S, Lesén E: Aspirin in cardiology - Benefits and risks. Int J Clin Pract (2009)63(3):468-477.
18. García Rodríguez LA, Hernández-Díaz S: Risk of uncomplicated peptic ulcer among users of aspirin and nonaspirin nonsteroidal antiinflammatory drugs. Am J Epidemiol (2004)159(1):23-31.
19. 12 receptor antagonist pharmacokinetics and pharmacodynamics: A foundation for distinguishing mechanisms of bleeding and anticipated risk for platelet-directed therapies. Thromb Haemost (2010)103(3):535-544.
20. Mega JL, Close SL, Wiviott SD, Shen L, Hockett RD, Brandt JT, Walker JR, Antman EM, Macias W, Braunwald E, Sabatine MS et al: Cytochrome P-450 polymorphisms and response to clopidogrel. N Engl J Med (2009)360(4):354-362.
21. Oqueli E, Hiscock M, Dick R: Clopidogrel resistance. Heart Lung Circ (2007)16(Suppl 3):S17-S28.
22. 12 receptor antagonist activity. Semin Thromb Hemost (2005)31(2):184-194.
23. Sugidachi A, Asai F, Ogawa T, Inoue T, Koike H: The in vivo pharmacological profile of CS-747, a novel antiplatelet agent with platelet ADP receptor antagonist properties. Br J Pharmacol (2000)129(7):1439-1446.
24. Sugidachi A, Asai F, Yoneda K, Iwamura R, Ogawa T, Otsuguro K, Koike H: Antiplatelet action of R-99224, an active metabolite of a novel thienopyridine-type Gi-linked P2T antagonist, CS-747. Br J Pharmacol (2001)132(1):47-54.
25. Eli Lilly & Co: Daiichi Sankyo and Lilly receive US FDA approval for effient. Press Release (2010): July 10.
26. Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S, Neumann FJ, Ardissino D, De Servi S, Murphy SA, Riesmeyer J et al: Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med (2007)357(20):2001-2015. • Discusses the results of the TRITON-TIMI 38 clinical trial, highlighting the superior efficacy of prasugrel compared with clopidogrel in preventing all-cause cardiovascular mortality in patients with ACS undergoing PCI. (Pubitemid 350106708)
27. Wiviott SD, Braunwald E, Angiolillo DJ, Meisel S, Dalby AJ, Verheugt FW, Goodman SG, Corbalan R, Purdy DA, Murphy SA, McCabe CH et al: Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel-Thrombolysis in Myocardial Infarction 38. Circulation (2008)118(16):1626-1636.
28. O'Donoghue M, Antman EM, Braunwald E, Murphy SA, Steg PG, Finkelstein A, Penny WF, Fridrich V, McCabe CH, Sabatine MS, Wiviott SD: The efficacy and safety of prasugrel with and without a glycoprotein IIb/IIIa inhibitor in patients with acute coronary syndromes undergoing percutaneous intervention: A TRITON-TIMI 38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel-Thrombolysis In Myocardial Infarction 38) analysis. J Am Coll Cardiol (2009)54(8):678-685.
29. Wiviott SD, Braunwald E, McCabe CH, Horvath I, Keltai M, Herrman JP, Van de Werf F, Downey WE, Scirica BM, Murphy SA, Antman EM: Intensive oral antiplatelet therapy for reduction of ischaemic events including stent thrombosis in patients with acute coronary syndromes treated with percutaneous coronary intervention and stenting in the TRITON-TIMI 38 trial: A subanalysis of a randomised trial. Lancet (2008)371(9621):1353-1363.
30. Murphy SA, Antman EM, Wiviott SD, Weerakkody G, Morocutti G, Huber K, Lopez-Sendon J, McCabe CH, Braunwald E: Reduction in recurrent cardiovascular events with prasugrel compared with clopidogrel in patients with acute coronary syndromes from the TRITON-TIMI 38 trial. Eur Heart J (2008)29(20):2473-2479.
31. Antman EM, Wiviott SD, Murphy SA, Voitk J, Hasin Y, Widimsky P, Chandna H, Macias W, McCabe CH, Braunwald E: Early and late benefits of prasugrel in patients with acute coronary syndromes undergoing percutaneous coronary intervention: A TRITON-TIMI 38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel-Thrombolysis In Myocardial Infarction) analysis. J Am Coll Cardiol (2008)51(21):2028-2033.
32. Wiviott SD, Braunwald E, Murphy SA, Antman EM: A perspective on the efficacy and safety of intensive antiplatelet therapy in the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel-Thrombolysis In Myocardial Infarction 38. Am J Cardiol (2008)101(9):1367-1370.
33. Antithrombotic efficacy and excess bleeding: A fine balance: HemOnc Today, Thorofare, NJ, USA (2008). www.hemonctoday.com/article.aspx?rid=28508
34. Bhatt DL: Prasugrel in clinical practice. N Engl J Med (2009)361(10):940-942. • Provides an insight into clinical trials that led to the approval of prasugrel and also suggests in which patient populations prasugrel would be beneficial.
35. 12 receptor antagonist for the prevention of thrombosis. Bioorg Med Chem Lett (2007)17(21):6013-6018.
36. 12 independently from ADP but antagonizes ADP-induced receptor signaling and platelet aggregation. J Thromb Haemost (2009)7(9):1556-1565.
37. Husted S, Emanuelsson H, Heptinstall S, Sandset PM, Wickens M, Peters G: Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: A double-blind comparison to clopidogrel with aspirin. Eur Heart J (2006)27(9):1038-1047. • Summarizes the findings of the phase II DISPERSE clinical trial, in which various doses of ticagrelor were compared with a single dose of clopidogrel in patients with atherosclerosis. At all doses, ticagrelor appeared to increase bleeding times, with no obvious dose-response relationship.
38. Siddique A, Shantsila E, Lip GY: AZD6140 and bleeding: Towards safer antiplatelet therapy? Int J Clin Pract (2009)63(4):537-539.
39. 12 antagonists. Semin Thromb Hemost (2005)31(2):195-204.
40. 12 receptor antagonist, in healthy subjects. Eur J Clin Pharmacol (2010)66(5):487-496.
41. Flierl U, Schöpp C, Jaitner J, Bauersachs J, Schäfer A: The novel P2Y12 antagonist AZD6140 rapidly and reversibly reduces platelet activation in diabetic rats. Thromb Res (2009)125(3):e93-e99.
42. 12 receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes. J Am Coll Cardiol (2007)50(19):1852-1856.
43. Storey RF, Husted S, Harrington RA, Heptinstall S, Wilcox RG, Gurbel PA, Grande P, Sanders N, Peters G, Emanuelsson H, Cannon CP: AZD6140 yields greater inhibition of platelet aggregation than clopidogrel in patients with acute coronary syndromes without previous clopidogrel treatment. J Am Coll Cardiol (2006)47(4)Suppl 1:Abs 821.
44. Gurbel PA, Bliden KP, Butler K, Tantry US, Gesheff T, Wei C, Teng R, Antonino MJ, Patil SB, Karunakaran A, Kereiakes DJ et al: Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: The ONSET/OFFSET study. Circulation (2009)120(25):2577-2585.
45. Schömig A: Ticagrelor - Is there need for a new player in the antiplatelet-therapy field? N Engl J Med (2009)361(11):1108-1111.
46. Doggrell SA: Ticagrelor, a platelet aggregation inhibitor for the potential prevention and treatment of arterial thrombosis and acute coronary syndromes. IDrugs (2009)12(5):309-317.
47. Amorini AM, Petzold A, Tavazzi B, Eikelenboom J, Keir G, Belli A, Giovannoni G, Di Pietro V, Polman C, D'Urso S, Vagnozzi R et al: Increase of uric acid and purine compounds in biological fluids of multiple sclerosis patients. Clin Biochem (2009)42(10-11):1001-1006.
48. Serebruany VL: The TRITON versus PLATO trials: Differences beyond platelet inhibition. Thromb Haemost (2009)103(2):259-261. •• Provides an indirect comparison of the TRITON and PLATO clinical trials, comparing the differences in clinical outcomes between prasugrel and ticagrelor, and identifying the important baseline characteristic differences between the two trials.
49. 12 receptor antagonist. Expert Opin Investig Drugs (2009)18(8):1219-1230. • Provides a concise review of the P2Y12 antagonist cangrelor, describing the structure and pharmacokinetics of cangrelor, as well as all the clinical trials in which cangrelor was tested.
50. Faxon DP: Antiplatelet therapy: Cangrelor for ACS - Lessons from the CHAMPION trials. Nat Rev Cardiol 7 (3): 124-125.
51. 12 antagonists. Curr Opin Hematol (2009)16(5):371-377.
52. 12 inhibitor, in healthy human subjects. AAPSJ (2008).
53. 12 inhibition. J Thromb Haemost (2009)7(Suppl 2):AS-TH-022.
54. Andre P, Jurek M, Sim D, DeGuzman F, Hollenbach S, Phillip DR, Conley PB: PRT060128, a novel, direct-acting orally available P2Y12 antagonist confers superior antithrombotic activity over clopidogrel in a mice thrombosis model. J Thromb Haemost (2007)5(Suppl 1):O-W-031.
55. *2 allele was associated with the HPR.
56. 12 ADP-receptor antagonist, before primary percutaneous intervention in patients with ST-elevation myocardial infarction: The Early Rapid ReversAl of platelet thromboSis with intravenous Elinogrel before PCI to optimize reperfusion in acute Myocardial Infarction (ERASE MI) pilot trial. Am Heart J (2009)158(6):998-1004.e1.
57. 12 antagonists, describing in detail the preclinical and clinical data available.
58. 12receptor-mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery disease. Eur Heart J (2008)29(1):21-30.
59. Hongo RH, Ley J, Dick SE, Yee RR: The effect of clopidogrel in combination with aspirin when given before coronary artery bypass grafting. J Am Coll Cardiol (2002)40(2):231-237.
60. Yende S, Wunderink RG: Effect of clopidogrel on bleeding after coronary artery bypass surgery. Crit Care Med (2001)29(12):2271-2275.
61. Dovlatova NL, Jakubowski JA, Sugidachi A, Heptinstall S: The reversible P2Y antagonist cangrelor influences the ability of the active metabolites of clopidogrel and prasugrel to produce irreversible inhibition of platelet function. J Thromb Haemost (2008)6(7):1153-1159.
62. Plavix Prescribing Information: sanofi-aventis, Paris, France (1997). products.sanofi-aventis.us/PLAVIX/PLAVIX.html
63. Effient Prescribing Information: Eli Lilly & Co, Indianapolis, IN, US (2009). pi.lilly.com/us/effient.pdf
64. Storey RF, Oldroyd KG, Wilcox RG: Open multicentre study of the P2T receptor antagonist AR-C69931MX assessing safety, tolerability and activity in patients with acute coronary syndromes. Thromb Haemost (2001)85(3):401-407.